China NMPA Product Recall - Drug infusion system

The National Medical Products Administration (NMPA) and the Shanghai Municipal Food and Drug Administration reported a voluntary recall by Medtronic Inc. of its SynchroMed II drug infusion systems. Publicized on April 8, 2014, this recall addresses a significant safety concern where the device may deliver medication at a rate exceeding the programmed setting by more than 14.5%, potentially leading to patient overdose. This issue results in incorrect drug dosages, with less medication drawn back than expected, affecting patients requiring long-term infusions. The cause of this pump malfunction is currently under investigation, and it has not yet been attributed to specific product batches, drugs, or geographic regions, with reported incidents occurring from five months post-implantation and continuing throughout the pump's lifespan. Medtronic Inc. is the manufacturer, with Medtronic Shanghai (Management) Co., Ltd. responsible for distribution in China. In response, regulatory bodies have requested all provincial, autonomous region, and municipal food and drug administrations to strengthen their supervision and management of similar medical products to ensure patient safety.